244 related articles for article (PubMed ID: 2047575)
1. Potentiation of pirarubicin cytotoxicity by dipyridamole in doxorubicin-resistant mouse P388 leukemia cells.
Furusawa S; Fujimura T; Kawauchi H; Sasaki K; Takayanagi Y
Res Commun Chem Pathol Pharmacol; 1991 Mar; 71(3):321-36. PubMed ID: 2047575
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP.
Bankusli I; Yin MB; Mazzoni A; Abdellah AJ; Rustum YM
Anticancer Res; 1989; 9(3):567-74. PubMed ID: 2764503
[TBL] [Abstract][Full Text] [Related]
3. [Augmentation of pirarubicin cytotoxicity by chlorpromazine in doxorubicin-resistant mouse P388 leukemia cells].
Shibata H; Sano F; Furusawa S; Kawauchi H; Sasaki K; Takayanagi Y
Yakugaku Zasshi; 1990 Sep; 110(9):678-81. PubMed ID: 2262880
[TBL] [Abstract][Full Text] [Related]
4. Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage.
Bellamy WT; Dalton WS; Kailey JM; Gleason MC; McCloskey TM; Dorr RT; Alberts DS
Cancer Res; 1988 Nov; 48(22):6365-70. PubMed ID: 3180056
[TBL] [Abstract][Full Text] [Related]
5. Differential effect of the calmodulin inhibitor trifluoperazine on cellular accumulation, retention, and cytotoxicity of anthracyclines in doxorubicin (adriamycin)-resistant P388 mouse leukemia cells.
Ganapathi R; Grabowski D; Rouse W; Riegler F
Cancer Res; 1984 Nov; 44(11):5056-61. PubMed ID: 6488165
[TBL] [Abstract][Full Text] [Related]
6. Modulation of doxorubicin-induced DNA lesions by verapamil, DMDP and dipyridamole in resistant P388 cell lines.
Yin MB; Bankusli I; Frank C; Rustum YM
Anticancer Res; 1990; 10(2A):327-32. PubMed ID: 2346306
[TBL] [Abstract][Full Text] [Related]
7. Resistance to adriamycin: relationship of cytotoxicity to drug uptake and DNA single- and double-strand breakage in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Goldenberg GJ; Wang H; Blair GW
Cancer Res; 1986 Jun; 46(6):2978-83. PubMed ID: 3698020
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of antitumor activity of pirarubicin by chlorpromazine in mice bearing doxorubicin-resistant P388 leukemia.
Shibata H; Maekawa I; Furusawa S; Kawauchi H; Takayanagi Y; Sasaki K
Res Commun Chem Pathol Pharmacol; 1990 Dec; 70(3):359-62. PubMed ID: 2093213
[TBL] [Abstract][Full Text] [Related]
9. [Modulation of anthracycline resistance by reserpine in P388 leukemia cells].
Shibata H; Furusawa S; Kawauchi H; Sasaki K; Takayanagi Y
Nihon Yakurigaku Zasshi; 1991 Jul; 98(1):1-6. PubMed ID: 1889760
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines.
Hait WN; Pierson NR
Cancer Res; 1990 Feb; 50(4):1165-9. PubMed ID: 2297765
[TBL] [Abstract][Full Text] [Related]
11. Effect of sodium chloride on pirarubicin induced cell killing in P388 mouse leukemia cells.
Furusawa S; Fujimura T; Hayasaka S; Kawauchi H; Sasaki K; Takayanagi Y
Res Commun Chem Pathol Pharmacol; 1991 Jul; 73(1):75-86. PubMed ID: 1882129
[TBL] [Abstract][Full Text] [Related]
12. Mechanism of acquired resistance to methotrexate in P388 murine leukemia cells and in their doxorubicin-resistant subline.
Ramu N; Ramu A; Cole DE; Balis FM; Poplack DG; Pollard HB
Isr J Med Sci; 1988; 24(9-10):477-82. PubMed ID: 2974448
[TBL] [Abstract][Full Text] [Related]
13. Modulation of subcellular distribution of doxorubicin in multidrug-resistant P388/ADR mouse leukemia cells by the chemosensitizer ((2-isopropyl-1-(4-[3-N-methyl-N-(3,4-dimethoxy-beta- phenethyl)amino]propyloxy)-benzenesulfonyl))indolizine.
Jaffrézou JP; Levade T; Chatelain P; Laurent G
Cancer Res; 1992 Dec; 52(23):6440-6. PubMed ID: 1423291
[TBL] [Abstract][Full Text] [Related]
14. Multifactorial resistance to adriamycin: relationship of DNA repair, glutathione transferase activity, drug efflux, and P-glycoprotein in cloned cell lines of adriamycin-sensitive and -resistant P388 leukemia.
Deffie AM; Alam T; Seneviratne C; Beenken SW; Batra JK; Shea TC; Henner WD; Goldenberg GJ
Cancer Res; 1988 Jul; 48(13):3595-602. PubMed ID: 2897875
[TBL] [Abstract][Full Text] [Related]
15. Oxygen radical detoxification enzymes in doxorubicin-sensitive and -resistant P388 murine leukemia cells.
Ramu A; Cohen L; Glaubiger D
Cancer Res; 1984 May; 44(5):1976-80. PubMed ID: 6324993
[TBL] [Abstract][Full Text] [Related]
16. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
Desai PB; Duan J; Sridhar R; Damle BD
Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648
[TBL] [Abstract][Full Text] [Related]
17. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes.
Ling YH; Priebe W; Yang LY; Burke TG; Pommier Y; Perez-Soler R
Cancer Res; 1993 Apr; 53(7):1583-9. PubMed ID: 8453627
[TBL] [Abstract][Full Text] [Related]
18. Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells.
Tsuruo T; Iida H; Kitatani Y; Yokota K; Tsukagoshi S; Sakurai Y
Cancer Res; 1984 Oct; 44(10):4303-7. PubMed ID: 6467192
[TBL] [Abstract][Full Text] [Related]
19. Combined effects of buthionine sulfoximine and cepharanthine on cytotoxic activity of doxorubicin to multidrug-resistant cells.
Kisara S; Furusawa S; Murata R; Ogata M; Hikichi N; Takayanagi Y; Sasaki K
Oncol Res; 1995; 7(3-4):191-200. PubMed ID: 8555653
[TBL] [Abstract][Full Text] [Related]
20. Electrophoretic mobility studies on doxorubicin-resistant and -sensitive murine P388 leukemic cells.
Nair S; Horton A; Leif RC; Krishan A
Cytometry; 1988 May; 9(3):232-7. PubMed ID: 3163971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]